1. Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies
- Author
-
Gadéa, Emilie, Thivat, Emilie, Wang-Lopez, Qian, Viala, Marie, Paulon, Rodolphe, Planchat, Eloise, Chadeyras, Jean-Baptiste, Merlin, Charles, Coudert, Benoit, Bignon, Yves-Jean, Morio, Béatrice, Durando, Xavier, Unité de Nutrition Humaine (UNH), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Institut National de la Recherche Agronomique (INRA), Ctr Invest Clin, Partenaires INRAE, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Equipe de recherche sur les traitements individualisés des cancers (ERTICa), Université d'Auvergne - Clermont-Ferrand I (UdA), UMR 990, Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), and Institut National de la Recherche Agronomique (INRA)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université
- Subjects
METFORMIN ,weight change ,[SDV]Life Sciences [q-bio] ,BODY-FAT ,IN-VITRO ,chemotherapy ,DIAGNOSIS ,INSULIN ,breast cancer ,PHYSICAL-ACTIVITY ,RECEIVING ADJUVANT CHEMOTHERAPY ,insulin resistance ,OLDER WOMEN ,GROWTH ,prognosis ,ENERGY-BALANCE - Abstract
National audience; Numerous studies have demonstrated that a significant change in weight during chemotherapy treatment was a factor of poor prognosis in early breast cancer women. However, the causes and mechanisms involved in this phenomenon are not fully known. This review summarizes current knowledge about the causes of energy imbalance during chemotherapy treatment and the mechanisms that have been proposed as responsible for the increased risk of relapse and death in this population. Current preventive strategies focus on physical activity programs but also on the use of metformin during and after chemotherapy.
- Published
- 2013